DocuSign Envelope ID: 7F25BA29-B6FC-47C0-8CFE-6EF47495143F

F0CD9BA9-1B7B-47AD-83F8-5D8BCF733EE1

Research title
Systematic review, meta-analysis and network meta-analysis comparing UroLift
Prostatic Urethral Lift (PUL) and other minimally invasive BPH surgical therapy.

Primary Investigator (PI)

Professor Eric Chung

Research hypothesis
UroLift PUL has equivalent efficacy in urinary domains but higher sexual domains scores
and better quality of life domains than other minimally invasive BPH surgical therapies.

Proposed study design

Critical review of all published English language papers on UroLift PUL, Rezum,
Aquablation, i-TIND and prostate artery embolization for treatment of BPH/LUTS.
1. Primary endpoints: Sexual function domains (erectile, ejaculatory, and orgasmic
functions and overall sexual satisfaction)
2. Secondary endpoint: Urinary outcomes (flow rates, IPSS scores), quality of life
domains (satisfaction rates, bothersome scores), cost, recovery period, and adverse
outcomes (recatheterisation/urinary retention, hematuria, UTI, readmission etc)

Inclusion/exclusion criteria
Inclusion criteria: All published studies including real-life data and company-sponsored
clinical trials. Emphasis is placed on randomised controlled trials.
Exclusion criteria: Narrative reviews or editorial opinion pieces

Recruitment plan
A trainee currently completing his MPhil degree is in the process of completing the literature
search based on relevant key words and compiling all the published articles under the
supervision of PI. All articles and data extraction into excel format will be supervised and
cross-checked by the PI.

Type of support requested

Financial educational support

Proposal and synopsis of research

To perform various systematic reviews, meta-analyses, and network meta-analyses to
compare the primary and secondary endpoints of various minimally invasive BPH surgical
therapies with specific emphasis on UroPift (PUL). Data will be obtained from published
studies with emphasis on randomised controlled trials. This unique project provides the
following benefits

1. Level 1 scientific evidence on the specific primary and secondary endpoints relating to the
contemporary minimally invasive BPH surgical therapies
2. Statistical analysis regarding superiority/non-inferiority/equivalence outcomes of UroLift
PUL compared to other contemporary minimally invasive BPH surgical therapies (Rezum,
Aquablation, i-TIND and prostatic artery embolization)
3. Addendum for submission to the Australia’s Medical Services Advisory Committee
(MSAC) regarding device and service funding

Research type
DocuSign Envelope ID: 7F25BA29-B6FC-47C0-8CFE-6EF47495143F
F0CD9BA9-1B7B-47AD-83F8-5D8BCF733EE1

Systematic review, meta-analysis, and network meta-analysis

Plans for publication

Aims for abstract presentations at major international meetings: USANZ 2022 @ Gold Coast,
Australia; UAA 2022 @ Sydney, Australia; ICS 2022 @ Vienna, Austria; and ISSM/SMSNA
WMSM 2022 @ Miami, USA)
Aims for publication at high impact scientific journals: Mid-late 2022

Proposed budget: $20,000

Statistical analysis: $10,000
Data collection, entry, and review: $5,000
Manuscript draft and publication: $5,000